TY - JOUR. T1 - Primary pancreatic cystic neoplasms revisited. Part I. T2 - Serous cystic neoplasms. AU - Sakorafas, George H.. AU - Smyrniotis, Vasileios. AU - Reid-Lombardo, Kaye M.. AU - Sarr, Michael G.. PY - 2011/6/1. Y1 - 2011/6/1. N2 - Primary pancreatic cystic neoplasms have been recognized increasingly during the two recent decades and include mainly serous cystic neoplasms, mucinous cystic neoplasms, and intraductal papillary mucinous neoplasms. Serous cystic neoplasms represent about 30% of all cystic neoplasms of the pancreas and are characterized by their microcystic appearance (on imaging, macroscopically, and microscopically) and their benign biologic behavior. Modern diagnostic methodology allows the preoperative diagnosis with an acceptable accuracy. Currently, indications for resection of serous cystic neoplasms of the pancreas include the presence of symptoms, size , 4 cm (because these large neoplasms have a more rapid growth rate and probably will soon become symptomatic), ...
To report on the perioperative outcomes of laparoscopic partial nephrectomy (LPN) for multilocular cystic renal cell carcinoma (MCRCC) and evaluate the feasibility of this minimally invasive technique as a potential gold standard treatment for MCRCC. We retrospectively reviewed the database of surgically pathological findings of patients who were diagnosed with MCRCC at Peking University First Hospital and Chinese PLA General Hospital (Beijing, China) between May 2009 and January 2013. A total of 42 patients with an average age of 48.3 years who were treated with LPN were collected. The patients perioperative outcomes were reported and analyzed. All operations were performed successfully without massive hemorrhage or open conversion. None of patients received lymph node dissection or metastasectomy. Two patients required postoperative transfusion with a mean amount of 175 cc packed red blood cells. Only three patients experienced mild postoperative complications. The mean operative time was 2.4 ± 1.2
Results 2622 patients were included. Seventy-four per cent were women, and median age at diagnosis was 58 years (16-99). Patients presented with non-specific abdominal pain (27%), pancreaticobiliary symptoms (9%), diabetes mellitus (5%), other symptoms (4%) and/or were asymptomatic (61%). Fifty-two per cent of patients were operated on during the first year after diagnosis (median size: 40 mm (2-200)), 9% had resection beyond 1 year of follow-up (3 years (1-20), size at diagnosis: 25 mm (4-140)) and 39% had no surgery (3.6 years (1-23), 25.5 mm (1-200)). Surgical indications were (not exclusive) uncertain diagnosis (60%), symptoms (23%), size increase (12%), large size (6%) and adjacent organ compression (5%). In patients followed beyond 1 year (n=1271), size increased in 37% (growth rate: 4 mm/year), was stable in 57% and decreased in 6%. Three serous cystadenocarcinomas were recorded. Postoperative mortality was 0.6% (n=10), and SCNs related mortality was 0.1% (n=1). ...
Cystic, mucinous, and serous neoplasms is a group of tumors. An example is cystadenoma. Cyst Mucinous, Mucous gland Serous, Serous ...
AIMS: Low-grade serous neoplasms of the testis are rare neoplasms that show striking morphological similarities with the better-understood ovarian neoplasms. This study is to see if there are similar molecular abnormalities in these two tumours. The cell of origin, relationship with serous ovarian tumour and the pathogenesis of these neoplasms are not fully established. METHODS AND RESULTS: As low-grade serous ovarian neoplasms are known to harbour mutations in the MAPK pathway, we investigated the involvement of BRAF and KRAS mutations in low-grade testicular serous tumour by performing mutational analysis of seven cases. Mutational analysis was performed by melting curve analysis followed by bidirectional sequencing. Our findings showed BRAF and/or KRAS mutations in three of the seven cases, which is similar to the proportions reported in low-grade ovarian serous neoplasms. Of these three cases, one showed co-mutation of BRAF and KRAS. CONCLUSION: The findings of this study are in support of a role of
Journal of Clinical and Diagnostic Research aims to publish findings of doctors at grass root level and post graduate students, so that all unique medical experiences are recorded in literature.
High-grade serous ovarian cancer, also known as high-grade serous carcinoma (HGSC), is the most common and deadliest type of ovarian cancer. HGSC appears to arise from the ovary, fallopian tube, or peritoneum. As most HGSC cases present with widespread peritoneal metastases, it is often not clear where HGSC truly originates. Traditionally, the ovarian surface epithelium (OSE) was long believed to be the origin of HGSC. Since the late 1990s, the fallopian tube epithelium has emerged as a potential primary origin of HGSC. Particularly, serous tubal intraepithelial carcinoma (STIC), a noninvasive tumor lesion formed preferentially in the distal fallopian tube epithelium, was proposed as a precursor for HGSC. It was hypothesized that STIC lesions would progress, over time, to malignant and metastatic HGSC, arising from the fallopian tube or after implanting on the ovary or peritoneum. Many clinical studies and several mouse models support the fallopian tube STIC origin of HGSC. Current evidence indicates
Missense mutation of TP53 is the dominant driver in ovarian/fallopian tube cancer [1-4]. Indeed TP53 is mutated in nearly all high grade serous carcinomas (HGSC), the histotype responsible for most deaths from ovarian cancer [5, 6], and is also mutated in its precursor, serous tubal intraepithelial carcinoma (STIC) [7-9], suggesting this is a key and early event in carcinogenesis [10]. In addition to inactivating wild type TP53 function, these mutations frequently confer gain-of -function properties including redirection of Nrf2 to upregulate the proteasome [11]. The aberrant metabolism of ovarian cancer cells produces an excess of misfolded proteins that are polyubiquitinated for targeted degradation via the proteasome, and this is associated with proteasome upregulation [12]. Consequently, ovarian cancer cells are both highly dependent on proteasome function and especially sensitive to treatment with a proteasome inhibitor [12-14]. The FDA-approved drug bortezomib, approved for the treatment ...
Tang S, Onuma, K, Deb P, Wang E, Mahe E, Sur M and Daya D. Frequency of Serous Tubal Intraepithelial Carcinoma in Various Gynecological Malignancies-A Study of 300 Consecutive Cases. Int J Gynecol Path, 2012; 31:103-110.. Quinlan -Davidson S, Hodgson N, Elavathil L, Tang S. Borderline Phyllodes Tumor with an Incidental Invasive Ductal Carcinoma and Lobular Carcinoma In-Situ Component: A Case Report". J Breast Cancer. 2011; 14(3):237-240. He SH, Chen X, Song CH, Liu ZQ, Zhou LF, Ma WE, Zhao LD, Li TL, Tang SG, Xing Z, Yang PC. Interferon- λ-mediates oral tolerance and inhibits antigen-specific, T-helper 2 cell-mediated inflammation in mouse intestine. Gastroenterology. 2011; 141:249-258. 2011. Feng BS, Chen X, Li P, Zheng PY, Chong J, Cho DB, He SH, Tang SG and Yang PC. Expression of integrin alphavbeta6 in the intestinal epithelial cells of patients with inflammatory bowel disease. North Am J Med Sci. 2009; 1: 200-204. 2009. Zheng PY, Feng BS, Oluwole C, Solderholm J, Chen X, Li P, Tang SG and ...
There are 5 clinical trials for malignant ovarian serous tumor, of which 5 are open and 0 are completed or closed. Of the trials that contain malignant ovarian serous tumor as an inclusion criterion, 1 is phase 1 (1 open), 2 are phase 2 (2 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open). BRCA1 and BRCA2 are the most frequent gene inclusion criteria for malignant ovarian serous tumor clinical trials [3]. ...
Text is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization ...
A multi-institutional study has identified a potential personalized treatment target for the most common form of ovarian cancer. In the December 8 issue of Cancer Cell, the research team describes finding that a gene called MAGP2 - not previously associated with any type of cancer - was overexpressed in papillary serous ovarian tumors of patients…
Intraductal papillary mucinous neoplasm (IPMN) is a type of tumor that can occur within the cells of the pancreatic duct. IPMN tumors produce mucus, and this mucus can form pancreatic cysts. Although intraductal papillary mucinous neoplasms are benign tumors, they can progress to pancreatic cancer. As such IPMN is viewed as a precancerous condition. Once an intraductal papillary mucinous neoplasm has been found, the management options include close monitoring and pre-emptive surgery.[medical citation needed] Pathologists classify intraductal papillary mucinous neoplasms (IPMNs) into two broad groups - those that are associated with an invasive cancer and those that are not associated with an invasive cancer. This separation has critical prognostic significance. Patients with a surgically resected intraductal papillary mucinous neoplasm without an associated invasive cancer have an excellent prognosis (>95% will be cured), while patients with a surgically resected intraductal papillary mucinous ...
TY - JOUR. T1 - Invasive carcinoma derived from intestinal-type intraductal papillary mucinous neoplasm is associated with minimal invasion, colloid carcinoma, and less invasive behavior, leading to a better prognosis. AU - Nakata, Kohei. AU - Ohuchida, Kenoki. AU - Aishima, Shinichi. AU - Sadakari, Yoshihiko. AU - Kayashima, Tadashi. AU - Miyasaka, Yoshihiro. AU - Nagai, Eishi. AU - Mizumoto, Kazuhiro. AU - Tanaka, Masao. AU - Tsuneyoshi, Masazumi. AU - Oda, Yoshinao. PY - 2011/5/1. Y1 - 2011/5/1. N2 - Objectives: Although intestinal-type intraductal papillary mucinous carcinoma (IPMC) is reported to have a better prognosis, few studies have addressed its invasive pattern. The meaning of "minimal invasion" (MI) in IPMC also remains unclear. We investigated the prognosis of intraductal papillary mucinous neoplasm (IPMN) focusing on MI and subtypes. Methods: We evaluated 71 patients with IPMC among a total of 179 patients with resected IPMN. Results: Although 2 of 10 MI-IPMC patients had lymph ...
Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathologic entity.: Intraductal papillary mucinous neoplasms represe
Expression of MUC4 Mucin Is Observed Mainly in the Intestinal Type of Intraductal Papillary Mucinous Neoplasm of the PancreasExpression of MUC4 Mucin Is Observed Mainly in the Intestinal Type of Intraductal Papillary Mucinous Neoplasm of the Pancreas ...
BACKGROUND Intraductal papillary mucinous neoplasms (IPMNs) may present with clinical and radiological pictures resembling those of chronic pancreatitis (CP). AIMS To compare the clinical and epidemiological characteristics of patients suffering from CP with those of patients suffering from IPMN. To assess whether CP is associated with an increased risk of developing IPMN. METHODS In our departments, from 1981 to 1998, we prospectively followed 473 patients suffering from CP, including 93 cases of chronic obstructive pancreatitis (COP), and 45 patients with a histologically confirmed diagnosis of IPMN. Another 6 patients had an initial diagnosis of CP and a subsequent diagnosis of IPMN. RESULTS Patients with IPMN were more often female (females 53 vs. 15%; p | 0.001), were older (mean age 63.1 vs. 42.8 years; p | 0.001), drank less alcohol (19 vs. 107 g/day; p | 0.001) and smoked fewer cigarettes (mean 8 vs. 21 cigarettes/day) than CP patients. These results were also confirmed when considering
Hruban RH, Takaori K, Klimstra DS, Adsay NV, Albores-Saavedra J, Biankin AV, Biankin SA, Compton C, Fukushima N, Furukawa T, Goggins M, Kato Y, Kloppel G, Longnecker DS, Luttges J, Maitra A, Offerhaus GJ, Shimizu M, Yonezawa S. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol. 2004 Aug;28(8):977-87 ...
article{41680afa-1eab-45c3-aa76-62b426b1b7aa, author = {Ansari, Daniel and Aronsson, Linus and Andersson, Roland}, issn = {1479-6694}, keyword = {biomarkers,gastrointestinal,molecular oncology,oncogenes,pancreatic biliary,surgery}, language = {eng}, month = {08}, number = {20}, pages = {1751--1753}, publisher = {Future Medicine Ltd.}, series = {Future Oncology}, title = {Biomarkers, imaging and multifocality in intraductal papillary mucinous neoplasms : Relevant for decision making?}, url = {http://dx.doi.org/10.2217/fon-2017-0244}, volume = {13}, year = {2017 ...
ASA 2018 Abstracts: Does Surgical Margin Impact Recurrence in Non-Invasive Intraductal Papillary Mucinous Neoplasms? A Multi-Institutional Study
Introduction IPMN is characterized by a predominantly noninvasive growth pattern with mucin production and cystic duct dilatation. The distinction between IPMN and pancreatic intraepithelial neoplasia (PanIN) ,which is the common precursor of invasive carcinomas
We have performed an in-depth single-cell phenotypic characterization of high-grade serous ovarian cancer (HGSOC) by multiparametric mass cytometry (CyTOF).
Intraductal papillary mucinous neoplasms (IPMN) are cystic neoplasms with the potential for progression to pancreatic cancer. Recognized by the global medical community just over two decades ago, IPMN have gained great epidemiological and clinical relevance thanks to the widespread use of cross-sectional abdominal imaging, which has led to a surge in the number of incidental pancreatic cysts being diagnosed. As our understanding of this disease has improved, we now know that some IPMN have a very elevated risk of cancer and require surgical resection, while others are low-risk lesions and can be followed ...
Xu, J., et al. Mass spectrometry-based peptidome profiling of human serous ovarian cancer tissues. The International Journal of Biochemistry & Cell Biology. S1357-2725(18)30258-9. 10/12/2018.. We identified 634 differentially expressed peptides, 508 of these peptides were highly abundant in serous ovarian cancer tissues, a result consistent with higher protease activity in ovarian cancer patients. The difference in preferred cleavage sites between the serous ovarian cancer tissues and normal ovarian epithelium indicates the characteristic peptidome of ovarian cancer and the nature of cancer-associated protease activity. Interestingly, KEGG pathway analysis of the peptide precursors indicated that the differentially regulated pathways in ovarian cancer are highly consistent with the pathways discovered in other cancers. Besides, we found that a proportion of the differentially expressed peptides are similar to the known immune-regulatory peptides and anti-bacterial peptides. Then we further ...
An ideal diagnostic approach would allow for the resection of only those lesions with present or near-future risk of malignancy, while excluding from surgery those individuals with either benign lesions or a prohibitive operative risk, thus minimizing the potential occurrence of mortality and morbidity associated with the surgical treatment of these cystic lesions. Recent advancements in imaging by CT, MRI, and endoscopic ultrasonography (EUS), linked with refinements in the pathological understanding of cystic neoplasms of the pancreas have furthered this effort. History and clinical criteria, such as age, gender, presence of symptoms, location of the neoplasm within the pancreas, as well as, morphology by cross-sectional imaging and cyst fluid analysis by EUS with fine-needle aspiration (EUS-FNA), all may play a role in the diagnosis of pancreatic cystic neoplasms and assessment of the need for resection. A recent analysis using decision analysis with Markov modeling has indicated that for ...
Study identifies cell-of-origin in the development of many ovarian tumors, including including high grade serous ovarian carcinoma (HGSOC)
title: Cripto-1 overexpression is involved in the tumorigenesis of gastric-type and pancreatobiliary-type intraductal papillary mucinous neoplasms of the pancreas, doi: 10.3892/or_00000184, category: Article
Detection of Pancreatic Cancer and Precancer by Stool DNA Testing: A Feasibility Study Recently, advances in DNA-based stool tests have made it possible to detect another type of cancer - colorectal neoplasia. Given these exciting advances, we are currently studying the effectiveness of DNA-based stool tests for the detection of pancreatic cancer and its precursor, intraductal papillary mucinous neoplasms (IPMN) in collaboration with Dr. David Ahlquists group at the Mayo Clinic.
Intraductal papillary mucinous neoplasms. You may not be familiar with the term, but these lesions in the pancreas, an organ that releases digestive enzymes and
Low grade serous ovarian cancer affects approximately 1 in 1000 women, many will be diagnosed in their 20s and 30s. With current medical treatments ...
Purpose: In high-grade serous ovarian cancer (HGSOC), higher densities of both B cells and the CD8+ T cell infiltrate were associated with a better prognosis. However, the precise role of B cells in the anti-tumor response remains unknown. As peritoneal metastases are often responsible for relapse, our aim was to characterize the role of B cells in the anti-tumor immune response in HGSOC metastases. Experimental Design: Unmatched pre and post-chemotherapy HGSOC metastases were studied. B-cell localization was assessed by immunostaining. Their cytokines and chemokines were measured by multiplex assay and their phenotype was assessed by flow cytometry. Further in vitro and in vivo assays highlighted the role of B cells and plasma cell IgGs in the development of cytotoxic responses and dendritic cell activation. Results: B cells mainly infiltrated lymphoid structures in the stroma of HGSOC metastases. There was a strong B-cell memory response directed at a restricted repertoire of antigens and ...
PMID: 26867183, PMCID: PMC5271177. "Integrated proteogenomic characterization of human high-grade serous ovarian cancer," H. Zhang, T. Liu, Z. Zhang, S. H. Payne, B. Zhang, J. E. McDermott, J. Y. Zhou, V. A. Petyuk. L. Chen, D. Ray, S. Sun, F. Yang, L. Chen, J. Wang, P. Shah, S. W. Cha, P. Aiyetan, S. Woo, Y. Tian, M. A. Gritsenko, T. R. Clauss, C. Choi, M. E. Monroe, S. Thomas, S. Nie, C. Wu, R. J. Moore, K. H. Yu, D. L. Tabb, D. Fenyo, V. Bafna, Y. Wang, H. Rodriguez, E. S. Boja, T. Hiltke, R. C. Rivers, L. Sokoll, H. Zhu, IeM. Shih, L. Cope, A. Pandey, B. Zhang, M. P. Snyder, D. A. Levine, R. D. Smith, D. W. Chan, K. D. Rodland, and CPTAC Investigators, Cell 166 (3): 755-765 (2016 ...
Specific preoperative diagnosis of pancreatic cystic neoplasms by CT alone is substantially inaccurate. Complementary tests such as EUS-FNA with fluid analysis and ERCP should be recommended to improve diagnosis especially if nonoperative treatment is planned.
RAD51D is a key player in DNA repair by homologous recombination (HR) and RAD51D truncating mutation carriers have an increased risk for ovarian cancer (OC). However, the contribution of non-truncating RAD51D variants to cancer predisposition remains uncertain. Using deep sequencing and case-control genotyping studies, we show that in French Canadians, the missense RAD51D variant c.620C,T;p.S207L is highly prevalent and is associated with a high risk for ovarian high-grade serous carcinoma (HGSC) (3.8% cases vs 0.2% controls). The frequency of the p.S207L variant did not significantly differ from that of controls in breast, endometrial, pancreas or colorectal adenocarcinomas. Functionally, we show for the first time that this mutation impairs HR by disrupting the RAD51D-XRCC2 interaction and confers PARP-inhibitor sensitivity. These results highlight the importance of a functional RAD51D-XRCC2 interaction to promote HR and prevent the development of HGSC. This study identifies c.620C,T;p.S207L ...
We have previously shown that WW domain-containing oxidoreductase (WWOX) has tumour-suppressing effects and that its expression is frequently reduced in pancreatic carcinoma. In this study, we examined WWOX expression in intraductal papillary mucinous neoplasm of the pancreas (IPMN) to assess the function of WWOX in pancreatic duct tumourigenesis using immunohistochemistry and methylation-specific polymerase chain reaction analysis. Among 41 IPMNs including intraductal papillary mucinous adenomas (IPMAs) and intraductal papillary mucinous carcinomas (IPMCs), loss or reduced WWOX immunoreactivity was detected in 3 (15%) of 20 IPMAs and 17 (81%) of 21 IPMCs. In addition, hypermethylation of the WWOX regulatory site was detected in 1 (33%) of 3 WWOX(−) IPMAs and 9 (53%) of 17 WWOX(−) IPMCs, suggesting that hypermethylation may possibly be important in the suppression of WWOX expression. Reduction of WWOX expression was significantly correlated with a higher Ki-67 labelling index but was not correlated
Cystic neoplasms of the pancreas represent about 10% of all cysts of the pancreas and ~1% of all pancreatic neoplasms. Much has been learned about the natural history and management of these tumors in the past decade. We are finding more of these lesions than in years past since so many patients receive ultrasounds or CT scans for other reasons and these tumors are found incidentally. Cystic neoplasms are subdivided into serous, mucinous and intraductal papillary mucinous neoplasms. These lesions are described separately on this website but a few generalities pertain to all. The most important aspect of these lesions is to recognize them. They must be differentiated from benign pancreatic cysts as the treatment is distinctly different. Differentiation of benign cysts from cystic neoplasms of the pancreas can usually be made by a good history and physical exam by a physician familiar with these disorders. If a cystic neoplasm is suspected and the patient is symptomatic (abdominal pain), surgical ...
High-grade serous ovarian cancer (HGSOC) is the most aggressive histological type of epithelial ovarian cancer, which is characterized by a high frequency of somatic TP53 mutations. We performed exome analyses of tumors and matched normal tissues of 34 Japanese patients with HGSOC and observed a substantial number of patients without TP53 mutation (24%, 8/34). Combined with the results of copy number variation analyses, we subdivided the 34 patients with HGSOC into subtypes designated ST1 and ST2. ST1 showed intact p53 pathway and was characterized by fewer somatic mutations and copy number alterations. In contrast, the p53 pathway was impaired in ST2, which is characterized by abundant somatic mutations and copy number alterations. Gene expression profiles combined with analyses using the Gene Ontology resource indicate the involvement of specific biological processes (mitosis and DNA helicase) that are relevant to genomic stability and cancer etiology. In particular we demonstrate the presence of a
Intraductal tubular adenoma of the pancreas, pyloric gland type (ITA), is an infrequent intraductal benign lesion located in the main duct and large branch duct of the pancreas. The purpose of this report is to introduce seven new cases and to compare their clinicopathologic features and KRAS mutations to gastric-type intraductal papillary mucinous neoplasms (IPMNs) and intraductal tubulopapillary neoplasms (ITPNs). Clinical findings, morphologic features, immunophenotypes and KRAS alterations were investigated in 7 patients with intraductal tubular adenomas, 16 patients with gastric-type intraductal papillary mucinous neoplasms and 6 patients with intraductal tubulopapillary neoplasms. There were more female patients in the ITA and gastric-type IPMN groups, whereas the opposite pattern was observed in the ITPN group. ITAs and gastric-type IPMNs were lined by columnar cells, similar to pyloric glands, with large extracellular deposits of mucin. ITPNs were polypoid and papillary mass located in the
Answer: Mucinous cystic neoplasm. Histology: This unusual neoplasm is has two distinct components. The stroma has the appearance of ovarian stroma, and indeed the stromal cells immunolabeled for estrogen and progesterone receptors. The second component is composed of epithelial cells. These cells are mostly cuboidal and occasionally have a "hobnail" appearance.. Discussion: Mucinous cystic neoplasms of the pancreas occur in women more frequently than they do in men, and mucinous cystic neoplasms have a distinctive "ovarian-type" of stroma. The neoplasm presented arose in a woman and it has ovarian stroma. One might expect that it is a classical mucinous cystic neoplasm, but two things are peculiar about this case. First, the epithelial cells do not form large cysts. Second, the epithelial cells are not columnar mucin-producing cells. Instead, they are mostly cuboidal and somewhat hob-nailed in appearance. This histologic appearance is almost identical to the mixed epithelial and stromal tumor ...
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Centers RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.. ...
Kosmahl M, Wagner J, Peters K, Sipos B, Kloppel G. Serous cystic neoplasms of the pancreas: an immunohistochemical analysis revealing alpha-inhibin, neuron-specific enolase, and MUC6 as new markers. Am J Surg Pathol. 2004 Mar;28(3):339-46 ...
Intraductal papillary mucinous neoplasms (IPMNs) are not fully understood, but are felt by many to be precursor tumors to full blown pancreatic cancer (ductal adenocarcinoma of the pancreas).. Thus, an interesting study was recently published by Italian researchers including Giovannetti and colleagues from the University of Pisa in the Annals of Oncology (the official journal of the European Society for Medical Oncology - ESMO) which examined the possible role of microRNAs as biomarkers for IPMNs.. The researchers examined and compared miR-21, miR-101, and miR-155 levels in 86 biopsy specimens of IPMNs. They additionally looked at relationships between these levels and overall survival and disease-free survival of the patients with these IPMNs.. The one microRNA that appeared to offer prognostic value as a biomarker in terms of IPMN risk was miR-21. The authors suggest that these results (especially involving miR-21) be further examined in future studies. ...
Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal cancers worldwide, partly because methods are lacking to detect disease at an early, operable stage. Noninvasive PDAC precursors called intraductal papillary mucinous neoplasms (IPMN) exist, and strategies are needed to aid in their proper diagnosis and management. Data support the importance of miRNAs in the progression of IPMNs to malignancy, and we hypothesized that miRNAs may be shed from IPMN tissues and detected in blood. Our primary goals were to measure the abundance of miRNAs in archived preoperative plasma from individuals with pathologically confirmed IPMNs and healthy controls and discover plasma miRNAs that distinguish between IPMN patients and controls and between "malignant" and "benign" IPMNs. Using novel nCounter technology to evaluate 800 miRNAs, we showed that a 30-miRNA signature distinguished 42 IPMN cases from 24 controls [area underneath the curve (AUC) = 74.4; 95% confidence interval (CI), 62.3-86.5, P = ...
Since the screening studies that investigated the utility of serum CA-125 and ultrasound did not improve survival rate, other screening modalities are aggressively pursued for ovarian HGSC.[13141518] Based on our current understanding of serous ovarian carcinogenesis, evidence pinpoints the etiologic significance of distal fallopian tubes.[111820] In keeping with this model, tubal lesions can potentially become a focal screening point for early detection of HGSC. Therefore, accurately detecting ovarian HGSC in its earlier stages is a promising concept which could provide earlier staging, adequate classification, and better prognostic outcomes. It has been shown that cytological diagnoses from fallopian fimbrial samples were correlative to histological diagnoses of HGSC.[18] However, due to the limited sample size that came from patients who already had clinical symptoms, the external validity is limited. Particularly given that the patients enrolled in those studies already had obvious clinical ...
title: Prediction of malignancy with endoscopic ultrasonography in patients with branch duct-type intraductal papillary mucinous neoplasm., doi: 10.1097/MPA.0000000000000177, category: Article
Background The presence of CD8+ tumor-infiltrating lymphocytes (TIL) is associated with prolonged survival in high-grade serous ovarian cancer (HGSC) and other epithelial cancers. Survival is most strongly associated with intraepithelial versus intrastromal CD8+ TIL, however the mechanisms that promote the intraepithelial localization of TIL remain poorly understood. We hypothesized that intraepithelial CD8+ TIL, like normal mucosal intraepithelial lymphocytes, might express CD103, a subunit of alpha7 integrin which binds E-cadherin on epithelial cells. Methods A large collection of primary ovarian tumors (HGSC, endometrioid, mucinous and clear cell) was analyzed by immunohistochemistry for the presence of TIL expressing CD103. The activation and differentiation status of CD103+ TIL were assessed by flow cytometry. The prognostic significance of TIL subsets was evaluated by Kaplan-Meier analysis. Results CD103+ TIL were present in all major ovarian cancer subtypes and were most abundant in HGSC. ...
PubMed journal article MUC2 expression and prevalence of high-grade dysplasia and invasive carcinoma in mixed-type intraductal papillary mucinous neoplasm of the pancrea were found in PRIME PubMed. Download Prime PubMed App to iPhone or iPad.
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
BACKGROUND & AIMS: Small nucleolar noncoding RNAs (snoRNAs) regulate function of ribosomes, and specific snoRNAs are dysregulated in some cancer cells. We investigated dysregulation of snoRNAs in pancreatic ductal adenocarcinoma (PDAC) cells. METHODS: We investigated snoRNA expression in PDAC cell lines by complementary DNA microarray and quantitative reverse transcription polymerase chain reaction. In PDAC (n = 133), intraductal papillary mucinous neoplasm (n = 16), mucinous cystic neoplasm-associated PDAC (n = 1), and non-tumor pancreas (n = 8) and liver (n = 3) tissues from subjects who underwent surgical resection, levels of snoRNA were measured by quantitative reverse transcription polymerase chain reaction and compared with clinicopathologic parameters and survival times determined by Kaplan-Meier analysis ...
Journal of Clinical and Diagnostic Research aims to publish findings of doctors at grass root level and post graduate students, so that all unique medical experiences are recorded in literature.